The US Patent and Trademark Office (USPTO) has granted a notice of allowance (NOA) to Echo Therapeutics' claimed application for its Prelude SkinPrep system and Symphony tCGM system.
The claimed Patent Application No. 10/792,862 entitled 'Method and Apparatus for Enhancement of Transdermal Transport' has been allowed, while the patent application entitled 'Transdermal Analyte Monitoring Systems and Methods for Analyte Detection' issued a Russian Patent No. 2444980.
Echo chairman and CEO Patrick Mooney said these new patents strengthen the company's patent portfolio for its non-invasive, glucose monitoring technology.
"We believe that our intellectual property portfolio will provide our products with long-term market protection and will add to shareholder value in the near- and long-term," Mooney added.
Symphony tCGM system, a non-invasive, wireless, transdermal continuous glucose monitoring system, is designed for patients with diabetes, while Prelude SkinPrep system for delivery of topical pharmaceuticals.
